Could a diabetes pill be the next heart attack lifesaver?
NCT ID NCT06174753
First seen Feb 25, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can reduce heart muscle damage in people having a severe heart attack (STEMI). About 256 participants will receive either the drug or a placebo right before a procedure to open blocked arteries. The main goal is to see if the drug shrinks the size of the heart injury, which could improve recovery and lower future risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y 4W7, Canada
Contact
Conditions
Explore the condition pages connected to this study.